Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Manipal Hospitals...

    Manipal Hospitals closes in to acquire Medanta stake at enterprise valuation 6000 crore

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-23T15:37:44+05:30  |  Updated On 16 Aug 2021 12:24 PM IST

    New Delhi: Manipal Hospital backed up by its investors TPG Capital and Temasek is heading closer to acquire Medanta Hospitals at a valuation of Rs 5800-6000 crore with some developement on the front expected in the coming few days.


    A recent report in Economic Times has confirmed that Last week at Medanta's board meeting, the proposal was discussed. However, the meeting ended inconclusively. Having said that, both sides are expected to sign a time-bound exclusivity agreement to conduct due diligence early next week, possibly even as early as this weekend, said multiple sources aware of developments to the daily

    Medanta, founded in 2009, operates super speciality hospitals and clinics across cities including Gurgaon, Lucknow, Indore, Ranchi and Sri Ganganagar. Founded by renowned cardiac surgeon Dr Naresh Trehan, Trehan and his family, along with co-founder Sunil Sachdeva own 55% of the share. US-based private equity fund Carlyle Group owns 27% in Medanta, while Singapore's Temasek Holdings Pte holds a share of 18%.


    ET adds that Manipal-TPG and Temasek are close to buying 82% stake in Medanta. It is expected that with the deal, Carlyle Group will completely exit from the deal, and the original promoter will also divest majorly while retaining a small portion.


    Also Read: Manipal eyes Medanta, Sets Valuation at Rs 6000 crore: Report

    "Carlyle, which was looking for a higher valuation, has finally agreed on the proposal last week and the Manipal-Medanta deal will go through quickly. The term sheet is expected to be signed in the next 8-10 days," one of the people said on the condition of anonymity told Economic Times


    Both TPG and Temasek will fund this transaction. They will invest a larger amount in Manipal Education & Medical Group(MEMG) to enhance their stake, which will in turn be invested in Medanta .TPG had invested about $146 million, or.Rs 900 crores, in February 2015 in MEMG and has a 22% stake while Singapore's investment company, Temasek, owns 18% of both Medanta and Manipal.


    Two months ago, the TPG-Manipal was seen vying for AMRI Hospitals Ltd (Advanced Medical Research Institute) in Kolkata. Manipal Hospitals had revived talks with FMCG major Emami Group to acquire its AMRI Hospitals Ltd. Emami looking for a valuation of Rs 800-1,000 crore for the hospital chain.

    Read Also: After losing Fortis Bid, Manipal vyes to buy AMRI for upto Rs 1,000 crore

    In recent times, Medanta has been under pressure because of price controls imposed by National Pharmaceutical Pricing Authority (NPPA). The holding company of Medanta, Global Health posted sales of Rs 1,278 crore in fiscal 2017, down from Rs 1,384 crore the year before, according to company filings. Profit after tax fell to Rs 54 crore in FY17 from Rs 175 crore in FY16. The group had total debt of Rs 182 crore by FY17.

    In August last year, the drug pricing regulator capped the prices of knee implants, reducing product prices by as much as 70% and had brought cardiac stents under price control in February to make them affordable. The price of drug-eluting stents drastically went down to about Rs 30,000 from over Rs 2 lakh, which evidently hit the revenues of all the hospitals in the country.

    Similarly, Medanta also saw a cry off in its revenue after several of its top doctors quit to join rivals such as Fortis and Max Healthcare Ltd.

    agreementcapitalCarlyleGlobal Healthgrowth rateHealthcarehospitalInvestmentManipal hospitalMedantamemgsharestakeTemasekTPGvaluation
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok